Home > IP News
Jan 20 (Reuters) - The U.S. Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review.
On a 7-2 vote, the justices said that the U.S. Court of Appeals for the Federal Circuit had not used the correct approach in analyzing whether the patent in question, due to expire in September 2015, was valid. (Reporting by Lawrence Hurley; Editing by Will Dunham)
To continue reading, click here.
(These latest Intellectual Property (IP) news and events presented here, are prepared and compiled by us, the World Patent & Trademark Law Office (WPTO),for your reference and information)